G Protein News and Research

RSS

Researchers design bioactive nanomaterial that promotes cartilage growth

Northwestern University researchers are the first to design a bioactive nanomaterial that promotes the growth of new cartilage in vivo and without the use of expensive growth factors. Minimally invasive, the therapy activates the bone marrow stem cells and produces natural cartilage.

1 Feb 2010

YM BioSciences-Cytopia merger complete

YM BioSciences Inc., announced that the merger of Cytopia Limited, the Australian biopharmaceutical company, into YM under a Scheme of Arrangement, has been concluded.

1 Feb 2010

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.

1 Feb 2010

New testing method for early detection of cancer

A new testing method is being developed to detect cancer soon after the tumor has formed. It will identify characteristic substances in the blood which accompany a certain type of tumor. The first steps in the development have already been completed.

1 Feb 2010

Study shows nutritional deficiency, stunted growth and obesity are common among Cameroonian teenagers

There are major differences in how well nourished Cameroonian teenagers are. Differences between city/countryside, boys/girls, and among individuals with high and low socio-economic status are described by Léonie Nzefa Dapi in the dissertation she is defending at Umeå University in Sweden.

1 Feb 2010

Oxford Nanopore Technologies raises $28M in new funding

Oxford Nanopore Technologies Ltd., a privately held company that is developing a disruptive technology platform for the electronic, label-free analysis of single molecules, today announced that it has raised £17.4 million ($28 million) in new funding.

From Oxford Nanopore Technologies 1 Feb 2010

IpAuctions to auction Predicant Biosciences patents, certain intellectual property of Perlegen

IpAuctions, Inc. is selling the patents and patent applications developed by Predicant Biosciences, formerly called BioSpect, and certain intellectual property of Perlegen.

1 Feb 2010

Musical video to teach basics of biotechnology

The video will be made available to high school students across North Carolina to help teach them how biotechnology harnesses cellular machinery to cure diseases, detect biohazards and manufacture new materials.

30 Jan 2010

Lanzoprazole and astemizole hold promise for early detection of AD

Investigators from the International Center for Biomedicine and the University of Chile, in collaboration with the Center for Bioinformatics of the Universidad de Talca, have discovered that two drugs, the benzimidazole derivatives lanzoprazole and astemizole, may be suitable for use as PET (positron emission tomography) radiotracers and enable imaging for the early detection of Alzheimer's Disease. The study is published in the current issue of the Journal of Alzheimer's Disease.

30 Jan 2010

New biomarker may predict treatment outcomes in RA patients

Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.

30 Jan 2010

PROLOR Biotech reports the EC approval of Merck's ELONVA

PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH) today noted the European Commission (EC) approval of Merck & Co., Inc.'s ELONVA®, a long-acting CTP-modified version of the fertility drug follicle stimulating hormone (FSH).

30 Jan 2010

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

30 Jan 2010

Docking algorithm EADock allows successful design of new inhibitors for anti-cancer target

Many human tumors express indoleamine 2,3-dioxygenase (IDO), an enzyme which mediates an immune-escape in several cancer types. Researchers in the Molecular Modeling group at the SIB Swiss Institute of Bioinformatics and Dr. Beno-t J. Van den Eynde's group at the Ludwig Institute for Cancer Research Ltd (LICR) Brussels Branch developed an approach for creating new IDO inhibitors by computer-assisted structure-based drug design. The study was presented in the January 2010 online issue of the Journal of Medicinal Chemistry.

30 Jan 2010

New study identifies that SynDIG1 plays critical role in creating and sustaining synapses

A new study from UC Davis Health System identifies for the first time a brain protein called SynDIG1 that plays a critical role in creating and sustaining synapses, the complex chemical signaling system responsible for communication between neurons.

30 Jan 2010

BBVA Foundation Frontiers of Knowledge Award granted to Robert J. Lefkowitz

The BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category goes in this second edition to Prof. Robert J. Lefkowitz (1943, New York, United States), investigator in the Department of Medicine at Duke University (United States).

29 Jan 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

New understanding of CD44 receptor's role in immune cell survival

Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a new way the cell surface protein, CD44, helps specific T helper (Th1) cells develop immunologic memory.

29 Jan 2010

Study sheds light on pancreatic cancer development and new potential drug targets

Researchers at the Moores Cancer Center at the University of California, San Diego, have found one reason that pancreatic cancer tumors are so difficult to treat with drugs. They have shown how a molecular switch steps up pancreatic cancer cell survival as well as resistance to a standard chemotherapy drug, and have identified alternate routes cancer cells take to avoid the effects of the therapy.

29 Jan 2010

Normal protein can be converted into prion that causes fatal brain diseases in humans

Scientists have determined how a normal protein can be converted into a prion, an infectious agent that causes fatal brain diseases in humans and mammals.

29 Jan 2010

UT-Battelle exclusively licenses patents on inventions based on Nell-1 gene

In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.

29 Jan 2010

G Protein News and Research

Researchers design bioactive nanomaterial that promotes cartilage growth

YM BioSciences-Cytopia merger complete

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

New testing method for early detection of cancer

Study shows nutritional deficiency, stunted growth and obesity are common among Cameroonian teenagers

Oxford Nanopore Technologies raises $28M in new funding

IpAuctions to auction Predicant Biosciences patents, certain intellectual property of Perlegen

Musical video to teach basics of biotechnology

Lanzoprazole and astemizole hold promise for early detection of AD

New biomarker may predict treatment outcomes in RA patients

PROLOR Biotech reports the EC approval of Merck's ELONVA

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

Docking algorithm EADock allows successful design of new inhibitors for anti-cancer target

New study identifies that SynDIG1 plays critical role in creating and sustaining synapses

BBVA Foundation Frontiers of Knowledge Award granted to Robert J. Lefkowitz

Global market for oncology drugs is forecast to reach $80 billion by 2050

New understanding of CD44 receptor's role in immune cell survival

Study sheds light on pancreatic cancer development and new potential drug targets

Normal protein can be converted into prion that causes fatal brain diseases in humans

UT-Battelle exclusively licenses patents on inventions based on Nell-1 gene

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News